Skip to main content
OpenTrials
Completed

NCT Number: NCT02372773

Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects

This study is being done to learn more about normal thinking and behavior, mild thinking and behavior problems, Frontotemporal Dementia and other forms of dementia in families in which one or more relatives have a mutation associated with Frontotemporal Dementia.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University of British Columbia, Vancouver, British Columbia, Canada

Loading trial locations.

About this study

This multicenter study will enroll 300 members of familial Frontotemporal Dementia (FTD) families across 8 experienced FTD research centers with a known mutation in MAPT, PGRN, or C9ORF72 (100 mutation carriers with mild dementia or minimally symptomatic yet non-demented, 100 asymptomatic mutation carriers, and 100 clinically normal relatives who are non-mutation carriers) to obtain annual assessments including T1-MRI, FLAIR, diffusion tensor imaging (DTI), ASL perfusion (ASLp), intrinsic connectivity functional MRI (icfMRI), MR spectroscopy (MRS), CSF, blood, and behavioral, neuropsychological and functional assessment, for a total of three assessments per participant.

A primary goal of this study is to identify the most robust and reliable methods to track disease progression in familial FTD so that disease-modifying therapeutic trials can be designed appropriately.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Must be a member of family with a known mutation in one of the three major FTLD related genes: MAPT, PGRN, or C9ORF72.
  • At least 18 years of age.
  • The predominant phenotype in the kindred must be cognitive/behavioral (ie, kindreds in whom parkinsonism or ALS is the predominant clinical phenotype among affected relatives may be excluded)
  • Have a reliable informant who personally speaks with or sees that subject at least weekly.
  • Subject is sufficiently fluent in English to complete all measures
  • Subject must be willing and able to consent to the protocol and undergo yearly evaluations over 3 years.
  • Subject must be willing and able to undergo neuropsychological testing (at least at baseline visit).
  • Subject must have no contraindication to MRI imaging.

Exclusion criteria

  • Known presence of a structural brain lesion (e.g. tumor, cortical infarct).
  • Presence of another neurologic disorder which could impact findings (eg, multiple sclerosis).
  • Subject is unwilling to return for follow-up yearly, undergo neuropsychological testing and MR imaging.
  • Subject has no reliable informant.

Treatment and study plan

Primary outcomes

  1. Rate of decline in traditional measures of clinical (neuropsychological and behavioral composites) function and cortical volume on structural MRI in the symptomatic phase of familial FTD

    Time frame: 5 years

    neuropsychological, clinical/behavioral, neuroimaging measures

Secondary outcomes

  1. Rate of decline in traditional measures of clinical (neuropsychological and behavioral composites) function and cortical volume on structural MRI in the asymptomatic phase of familial FTD

    Time frame: 5 years

    neuropsychological, clinical/behavioral, neuroimaging measures

  2. Value of novel imaging and clinical measures for characterizing asymptomatic familial FTD subjects, and factors predicting clinical rates of progression in each group.

    Time frame: 5 years

    neuropsychological, clinical/behavioral, neuroimaging measures

  3. Genetic and biofluid factors that modify rates of clinical and neuroimaging decline in the asymptomatic and symptomatic phases of familial FTD.

    Time frame: 5 years

    genetic and biolfuid factors

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Collaborators

  • National Institute of Neurological Disorders and Stroke (NINDS)
  • National Institute on Aging (NIA)

Registry information

Acronym: LEFFTDS

Important dates

Study start
2015
Primary completion
2020
Study completion
2020
First posted
Feb 26, 2015
Registry last updated
Aug 3, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.